Home
 /
Papers
 /
Biochemistry
 /
A Cryptic Interfacial Pocket Uncovered in Full CRL4CRBN–IKZF3 Ubiquitylation Complex Enhances IMiD Efficacy
Preprint
Open access
Top 1% · Validated by QED

A Cryptic Interfacial Pocket Uncovered in Full CRL4CRBN–IKZF3 Ubiquitylation Complex Enhances IMiD Efficacy

Zhiheng Deng, Huasong Ai, Qiang Shi +11 more
June 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.06.08.658527
99
%
QED Score
QED Impressions

Capturing the first fully assembled, catalytically active CRL4CRBN ubiquitylation complexes across eight clinical IMiDs, this study reveals a cryptic interfacial pocket invisible in partial structures, unlocking structure-guided engineering of next-generation molecular glue degraders.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

Cryo-EM structures of eight IMiDs in full CRL4CRBN ubiquitylation complexes reveal that next-generation IMiDs achieve enhanced therapeutic efficacy by simultaneously engaging both the canonical CRBN TBD pocket and a cryptic gluing-driven interfacial (GDI) pocket formed by the IKZF3 non-degron ZF3 motif, providing a structural basis for rational design of improved molecular glue degraders with enhanced potency and selectivity.

See full analysis
Main Claim 1 –

Eight IMiDs Form Conserved Active CRL4CRBN–IKZF3 Ubiquitylation Assemblies

Supporting evidence

  • IMiDs Vary in IKZF3 Degradation Potency; Four Are Strongest
  • IKZF3 K166 Is the Primary IMiD-Induced Ubiquitylation Site
Main Claim 2 –

All IMiDs Conservedly Bind CRBN TBD and IKZF3 ZF2

Supporting evidence

  • CRL4CRBN Conformational Plasticity Accommodates Diverse IMiDs
Main Claim 3 –

Next-Generation IMiDs Engage Cryptic IKZF3 ZF3 GDI Pocket

Supporting evidence

  • IKZF3 ZF3 Is Required for Efficient IMiD-Induced Degradation
  • IKZF3 R186 Mediates GDI Pocket Binding by Bridging IMiDs
  • CRBN Lon H103 Is Essential for GDI Pocket Ubiquitylation
Main Claim 4 –

Full CRL4CRBN Docking Predicts IKZF3 IMiD SAR Better

Supporting evidence

  • GDI Pocket Fit Drives IMiD Substrate Selectivity Versus GSPT1/CK1α

Abstract

Immunomodulatory imide drugs (IMiDs) redirect the CUL4–RBX1–DDB1–CRBN (CRL4CRBN) ligase to ubiquitylate and degrade disease-linked proteins, but the full picture of how IMiDs glue the neosubstrate within the whole CRL4CRBN complex remains unknown. We determined cryo-electron microscopy structures of eight approved or clinical IMiDs in full CRL4CRBN ubiquitylation complexes at resolutions up to 3.4 Å, and revealed how these structurally distinct IMiDs exploit the structural plasticity of CRL4CRBN to organize conformationally conserved and compact active ubiquitylation assemblies with the neosubstrate IKZF3. Four “next-generation” IMiDs were found to additionally engage a cryptic gluing-driven interfacial (GDI) pocket at the non-degron zinc finger 3 (ZF3) of IKZF3, which contributes to their enhanced efficacy and neosubstrate specificity. The identification of cryptic gluing-driven pockets formed only in full ubiquitylation complexes provides new structure-directed design opportunities for IMiDs to improve therapeutic efficacy.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?